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Filamentous phage displaying peptides representing single epitopes of the glycoprotein G of HSV-2 (gG2) were used as
immunogens via the subcutaneous route in Balb/c mice without additional adjuvant. The phage were isolated from a random
phage peptide display library and contain 15-mer peptide inserts that mimic epitopes of gG2. In each case, an antibody
response to gG2 was generated that was dependent on the dose of phage administered and on the presence of the peptide
insert. Phage displaying epitopes of gG2, which map to amino acids 551–570, were the most immunogenic; interestingly, this
region of gG2 is frequently recognised by patients infected with HSV-2. The data also provide interesting information as
regards choice of peptide mimics for use as immunogens because, surprisingly, the most antigenic of the individual clones
was the least immunogenic. In two of the experiments, mice immunised with phage displaying a single epitope of gG2 were
protected against challenge with a lethal dose of whole HSV-2. This suggests a possible role for phage-displayed peptides
in inducing protective immunity against pathogens and provides a model system for investigating the underlying mecha-
nisms. © 2000 Academic PressINTRODUCTION
Filamentous bacteriophage may be engineered to ex-
press peptides as N-terminal fusions of the coat proteins
pIII and pVIII. Whereas pIII is present in only five copies
per virion, pVIII is represented by 2700 copies and is a
more favoured site for the introduction of peptides for the
purpose of immunisation (Willis et al., 1993; Veronese et
al., 1994; Meola et al., 1995). The N-terminal 20 amino
acids of pVIII are exposed on the surface of the phage.
Small peptides, up to ;5 amino acids in length, can be
inserted close to the N terminus without disrupting
phage assembly (Greenwood et al., 1991). However, in-
sertion of larger peptides can only be achieved using a
phage construct with two copies of gene VIII, one en-
coding the wild-type protein and a second encoding pVIII
displaying the insert peptide. Both are incorporated in
the phage particle with the recombinant pVIII accounting
for #30% of the expressed protein.
To date, studies of natural and experimentally induced
immunity to herpes simplex virus (HSV) have revealed a
complex picture involving multiple proteins such as gB
and gD (Stanberry, 1995; McKenzie and Straus, 1996),
and the likely involvement of cell-mediated as well as
antibody-mediated immunity in protection against pri-
mary infection or reactivation (Watari et al., 1998; Brehm
1 To whom correspondence should be addressed. Fax: 0115
709233. E-mail: anna.grabowska@nottingham.ac.uk.
2 Present address: Actinova Ltd., Cambridge, UK.
47et al., 1997). Accordingly, attempts to develop a vaccine
against HSV type 2 (HSV-2) have focused on live atten-
uated virus containing whole virion particles or whole
proteins. We have previously identified phage clones that
express peptides that mimic single epitopes of the gly-
coprotein G of HSV-2, gG2 (Grabowska et al., 1999). We
now report the observation that these relatively simple
peptide antigens, fused to phage virions, confer protec-
tive immunity in a live challenge model of HSV-2 infec-
tion. This is the first demonstration that peptides discov-
ered and displayed on phage can be used to confer
protective immunity against an infectious agent and sup-
port the view that this approach may be generally useful
as a discovery and delivery tool for the development of
novel vaccines.
RESULTS
In an initial experiment, eight groups of three mice
were immunised on two occasions with a pool of three
phage clones, 2.10, 2.11, and 3.19. These phage had been
previously selected by biopanning a phage library
against the anti-gG2 monoclonal antibody (mAb), H5
(Grabowska et al., 1999). Each clone displays a different
peptide (Table 1) that represents the epitope of gG2
recognised by H5. The phage were prepared individually
by polyethylene glycol (PEG) precipitation and pooled;
half of the pool was absorbed against polymixin B to
remove contaminating lipopolysaccharide (LPS), which
may be toxic to mice. Both of these preparations were
used as immunogens at one of four doses (100, 75, 50, or
0042-6822/00 $35.00
Copyright © 2000 by Academic Press
All rights of reproduction in any form reserved.
o
m
8
p
g
t
g
i
E
1
p
l
W
w
3
2
n
H
e
e motif
native”
48 GRABOWSKA ET AL.10 mg). The antibody response to wild-type phage and
gG2 in each group of mice was measured by ELISA in
prebleeds and in sera obtained from blood collected 2
weeks following the last immunisation. The results are
shown in Figs. 1a and 1b. Antibodies to both wild-type
phage (f88-4) and gG2 could be detected in a number of
mice in each group. In general, there was a stronger
response in the mice immunised with unabsorbed com-
pared with absorbed phage, and a larger dose of im-
munogen gave rise to a higher level of antibodies. The
percentage survival within each group, 14 days after
lethal challenge, is shown in Fig. 1c. At the two highest
phage doses (100 and 50 mg) all mice survived, and with
decreasing phage doses survival decreased, suggesting
that protective immunity to HSV-2 can be induced by
immunisation with phage clones displaying peptides that
mimic a single epitope of gG2. Because no toxic effects
attributable to LPS were observed, all remaining exper-
iments were carried out with phage that had not been
absorbed against polymixin B.
Three additional experiments were carried out to fur-
ther investigate the ability of phage-displayed peptides
to stimulate production of antibodies to gG2 and to pro-
tect against lethal challenge with HSV-2. In each exper-
iment, groups of 10 mice were given three immunisations
at 2-week intervals with phage displaying epitopes de-
rived from gG2, as follows: (a) the pool of H5 phage
clones (2.10, 2.11, and 3.19) at doses ranging between 1
and 300 mg. (b) three pools of phage clones, each at 30
T
Sequences of the Inserts of the
mAb Phage
H5 2.10 M D D D T E
2.11 X P P F T S A V
3.19 S T T N T P L V
Motif
Native 551 A
H7 7.17 Q P T S K P T R
7.25 N A E T A
F11 8.13
8.22 A L S S Q G
9.4
Motif
Native
E5 12.4 Y M Q
12.18 S P
12.28
Motif
Native
Note. For each phage clone, the sequence of the 15 amino acid pep
the standard single letter amino acid code. In addition, for each mAb th
shown to contain the epitope is shown. Lower case numbers on the “r 100 mg, representing epitopes defined by other gG2
Abs (H7, F11, and E5, respectively): 7.17 and 7.25; 8.13,
t
(.22, and 9.4; and 12.4, 12.18, and 12.28. (c) Individual
hage clones from the H5 pool, each at 30 or 100 mg.
In addition, groups were immunised with wild-type
phage (f88-4) to ensure that the response generated was
dependent on the peptide insert displayed by the phage
or with Tris-buffered saline (TBS) as a control for the
lethal challenge. In both (b) and (c), mice immunised with
the H5 pool were also included to allow comparison
between experiments.
Figure 2 shows the reactivity of sera from these mice
with gG2. In comparison with the level of response in the
prebleeds, a clear dose-dependent response to the phage-
displayed peptides was observed, with saturation of the
response at a dose of 100 mg (Fig. 2a). Some reactivity to
G2 could be detected in mice immunised with f88-4, but
his response was low compared with the level of antibody
enerated in response to the same dose of phage display-
ng H5-reactive peptides. Phage displaying the H7, F11, and
5 epitopes were also immunogenic, especially at the
00-mg dose, but while the response to the E5 pool of
hage was comparable to that observed for the H5 pool, a
ower response to the H7 and F11 pools was found (Fig. 2b).
hen individual clones from the H5 pool were tested, there
as again a clear hierarchy of immunogenicity with clone
.19 being the most immunogenic and 2.10 the least (Fig.
c). This was a surprising result given the relative antige-
icity of the phage clones as measured by their binding of
5 in ELISA (Fig. 3a), though this may relate to the appar-
ntly high level of expression of the recombinant pVIII in
Clones Used as Immunogens
Sequence of insert
P T H R S L P
V D H R S
L E H R S
L E H R S
P E H R G G P E E F E G A G D G 570
L V S F L
L S S F P P S P
T P E S T P L L P P F P R S V
S P E P T P L
Y T P Q T S L E L P P E S F
T P L
359 P E K T P L P V S A T A M A P S V D P S378
P P P P L H A P D Y
E P P P E H R A L V P
S T P T E H T Y P L E I I T
P P P E H
P P P P E H R G G P E E F E G A G D G570
xpressed as an insert in the phage major coat protein, is given using
common to phage clones selected by the mAb and the gG2 sequence
sequence lines indicate amino acid positions within gG2ABLE 1
Phage
R F
G G
S H
P P P
P W
F S
G M
D
P D
L P
T
551A
tide, ehis clone as analysed by silver staining of Tris–tricine gels
Fig. 3b).
49INDUCTION OF PARTIAL PROTECTIVE IMMUNITY TO HSV-2 BY PHAGE-DISPLAYED PEPTIDESFollowing each of these immunisation experiments,
the mice were again challenged with a lethal dose of
HSV-2 and monitored over the following 14 days. In the
groups immunised with a range of doses of phage
displaying H5-reactive peptides protection was sporadic,
and similar or higher levels of survival were observed in
the groups immunised with wild-type phage. High levels
of survival (.70%) were seen in the experiment in which
mice were immunised with phage displaying peptides
FIG. 1. The antibody response to wild-type phage (a) or gG2 (b)
measured by ELISA and the percentage survival within each group of
mice 14 days after challenge with a lethal dose of HSV-2 (c) are shown.
Mice were immunised with a range of doses of the pool of phage
clones (2.10, 2.11, and 3.19) displaying phage representing the H5
epitope of gG2. The phage preparation was either used immediately
following PEG precipitation (unabsorbed) or following absorption
against polymixin B to remove LPS (absorbed). Each point represents
the result for an individual animal.representing other epitopes of gG2 in both test and
control groups, suggesting that the challenge dose ofvirus was inadequate, and thus no conclusions could be
drawn as to the efficacy of these immunogens in provid-
ing protection. However, in the final experiment in which
groups of mice were immunised with phage displaying
H5-reactive peptides, differences in the survival rates
FIG. 2. Anti-gG2 responses measured by ELISA for mice immunised
with a range of doses of the H5 pool of clones (a); three further pools
of phage clones displaying epitopes defined by the anti-gG2 mAbs H7,
F11, or E5 (b); individual phage clones 2.10, 2.11, or 3.19 from the pool of
H5 clones (c). Control immunogens included the wild-type phage f88-4
and TBS. Each point represents the result for an individual animal. For
each group, the median of the responses of individual animals within
that group is shown as a horizontal line.
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50 GRABOWSKA ET AL.between the control groups and the experimental groups
could be seen. The survival of each of the groups of mice
in this experiment over the 17 days following lethal chal-
lenge is shown in Fig. 4. At the end of the 17-day period,
FIG. 3. Characterisation of individual clones from the H5 pool. (a) The
ntigenicity of the clones was assessed by measuring their reactivity
ith the mAb H5 by ELISA. An irrelevant antibody 1C12 and the
ild-type phage f88-4 were used as negative controls. (b) The relative
evels of expression of the recombinant and wild-type pVIII were mea-
ured by silver staining of the separated phage proteins on Tris–Tricine
AGE gels. The wild-type protein VIII (labelled wt pVIII) was identified
y comparison with staining of the wild-type phage pVIII. The larger
ands visible in the 2.10 and 3.19 tracks represent the recombinant
VIII. The recombinant pVIII was not visible for 2.11.
FIG. 4. The percentage survival of immunised mice over a 17-day per
with 30 or 100 mg of the individual phage clones 2.10, 2.11, or 3.19 or a pool of
immunised with the wild-type phage f88-4 or TBS. The percentage survival oonly 20% of the mice in the control groups, immunised
with wild-type phage or TBS, were still alive, in contrast
with 40–60% of the mice immunised with individual
phage clones or 100 mg of pooled phage and 80% of
ice given 30 mg of the pool of phage. For this experi-
ment, the survival times of mice immunised with 100 or
30 mg of phage displaying HSV peptides were compared
with those of mice receiving 100 or 30 mg of wild-type
phage, respectively, or TBS only, using the Mann–Whit-
ney test. Statistical significance (P # 0.05) was
achieved when the group immunised with 30 mg of the
ool of phage was compared with those receiving 30 mg
of wild-type phage or TBS alone and when the group
receiving 100 mg 2.10 was compared with those receiving
00 mg wild-type phage or TBS alone. The comparisons
were also approaching significance (P , 0.1) for the
roups immunised with 100 mg of 2.11 and 100 mg of the
ool of phage.
DISCUSSION
Immunisation of mice with pools of phage clones, or
ndividual phage clones, displaying 15 amino acid pep-
ides representing single epitopes of gG2 resulted in a
erum antibody response to gG2. The level of the anti-
G2 antibody response observed was dependent on the
hage dose administered and increased with succes-
ive immunisations (data not shown). The anti-gG2 reac-
ivity of sera from mice immunised with equivalent doses
f the wild-type phage f88-4 was low; this shows that the
esponse to the phage displaying gG2 epitopes is due to
he displayed epitopes rather than components of the
wing lethal challenge with HSV-2. Groups of 10 mice were immunisediod follo
the three phage clones, recognised the mAb H5. Control groups were
n Day 17 is also shown.
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51INDUCTION OF PARTIAL PROTECTIVE IMMUNITY TO HSV-2 BY PHAGE-DISPLAYED PEPTIDESphage. The peptides displayed by the phage are, there-
fore, not only antigenic, i.e., able to mimic this gG2
epitope, but are also immunogenic.
The peptides displayed by these phage are not de-
rived from the native sequence of gG2. The phage clones
were selected from a random phage peptide display
library by four mouse monoclonal antibodies and mimic
four discrete epitopes of gG2 (Grabowska et al., 1999).
The phage selected by mAbs H5, E5, and F11 display
peptides with some similarity to the native sequence of
gG2 over only part of their length, approximately 3–5
amino acids (see Table 1). Therefore the majority of the
amino acids within the 15 amino acid peptide inserts are
not part of the epitopes though they may be required to
maintain the antigenicity or immunogenicity of the pep-
tide, for example, by contributing to the folding of the
peptide. Different degrees of immunogenicity were ob-
served with different phage clones or pools of clones.
Interestingly, the H5 and E5 clones, both derived from a
region of gG2 (amino acids 551–570) that is recognised
by a large proportion of patients infected with HSV-2
(Marsden et al., 1998; Grabowska et al., 1999), were the
most immunogenic, though antibodies were also gener-
ated in response to the F11 and H7 clones, which map to
amino acids 351–427 and amino acids 569–588 of gG2,
respectively (Grabowska et al., 1999). The three H5
clones were also used individually as immunogens. Sur-
prisingly, the phage clone 2.10, which is the most anti-
genic, as defined by its reactivity with mAb H5 in ELISA,
was the least immunogenic. This may be accounted for
by the apparently low level of expression of the recom-
binant peptide-displaying pVIII in this phage clone be-
cause the most immunogenic of the clones, 3.19, had the
highest level of expression of the recombinant pVIII;
however, one would expect that low levels of expression
would also adversely affect the antigenicity of clone 2.10.
In these experiments, phage were administered with-
out any additional adjuvant. The phage preparations
used are likely to contain some bacterial contaminants. It
will be of interest to find out whether these or compo-
nents of the phage itself are able to provide an adjuvant
effect. Certainly the overall levels of antibody were lower
in mice given phage preparations that had been preab-
sorbed against polymixin B to remove LPS. Willis et al.
(1993), showed that the immune response to phage-
displayed peptides was T-cell dependent. Presumably,
this T-cell help is provided by components of the phage
or bacterial contaminants and may be involved in direct-
ing the immune response towards a Th1 or Th2 type of
response.
In two of the experiments, protection against lethal
challenge with HSV-2 was observed. In one experiment,
protection correlated well with the dose of the H5 pool of
phage used, with 100% of the mice receiving the highest
doses surviving beyond Day 14 and lower survival rates
in groups of mice receiving lower doses. In another
i
aexperiment, again using the H5 phage clones, as a pool
or as individual clones, while the overall survival rates
were lower, the protection observed was dependent on
the presence of the insert peptide because use of wild-
type phage gave rise to lower levels of survival equiva-
lent to those in mice immunised with buffer alone. How-
ever, this effect was difficult to reproduce; in one of the
two remaining experiments, survival levels were high in
all groups possibly because the lethal challenge dose
used was too low, and in the other, the protection was
inconsistent with no correlation between protection and
either the dose or nature of the immunogen. In addition,
in the experiments where protection was observed, there
was no obvious correlation between the level of antibody
to gG2 induced and the degree of protection: animals
receiving the unabsorbed phage preparation and those
receiving a preparation preabsorbed against polymixin B
to remove LPS were protected, even though the levels of
antibody generated in the latter were considerably lower;
and protection was highest in mice that had been given
a 30-mg dose of the pool of H5 phage (Fig. 4), while
tronger anti-gG2 responses were seen in other groups
hat had lower survival rates (Fig. 2c).
It is possible that, to some extent, the variability in the
rotection is related to use of different phage prepara-
ions with differing degrees of bacterial contamination in
ifferent experiments. If such molecules do provide an
djuvant effect, there may be subtle differences between
he anti-gG2 responses generated in different experi-
ents, for example, in the relative proportions of different
sotypes of antibodies. Cell-mediated immune mecha-
isms have also been shown to contribute to protection
gainst HSV-2 infection (Schmid and Rouse, 1992); in the
resent study, measurement of cellular immune re-
ponses was not attempted because these phage do not
ontain significant lengths of sequence derived from the
ative protein, and therefore it seemed unlikely that the
echanism involved in the observed protection is cell-
ediated; however, this remains to be formally proven.
ecause this is a biological model, it is also possible that
ariation between the experiments in terms of the sur-
ival observed is related to other factors that affect sus-
eptibility of the mice to lethal challenge such as minor
ifferences in age and size of the animals and the dose
f virus used for the lethal challenge.
While it has been shown previously that phage ex-
ressing peptides derived from viral proteins (Willis et
l., 1993; Veronese et al., 1994) or expressing mimotopes
f epitopes from viral proteins are able to induce an
ntibody response to the native protein (Meola et al.,
995), it has not been demonstrated previously that they
an induce protection against challenge with virus. It is
triking that phage displaying single epitopes are able tonduce protection against a whole virus. Here we have
chieved similar levels of protection to those achieved
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52 GRABOWSKA ET AL.previously using a whole baculovirus-expressed glyco-
protein G (Ghiasi et al., 1992).
There has been considerable interest in the use of
glycoproteins derived from HSV-2 as subunit vaccines for
use in humans both to protect against HSV-2 infection
and to reduce the frequency and severity of recurrent
episodes of disease (Stanberry, 1995; McKenzie and
Straus, 1996). Previous work with candidate subunit HSV
vaccines has concentrated on the glycoproteins B and D
as these contain numerous type-common epitopes and,
thus, are likely to stimulate protection against both HSV-1
and HSV-2. The experiments described here suggest that
the glycoprotein G is a potential vaccine candidate. The
present study also has implications for the development
of a prophylactic vaccine against HSV-2. The current
study emphasises the likely importance of type-specific
antibodies in protection against primary infection by
HSV-2, as observed in previous studies of protection
against neonatal infection by transplacentally acquired
maternal antibodies (Ashley et al., 1992), and suggests
novel approaches to the development of an HSV-2 vac-
cine that focuses the attention of the immune system on
type-specific epitopes even in the context of an immune
system primed to respond to type-common epitopes.
The experiments we have described may provide a
model system for investigating the potential role of
phage in inducing protective immunity against patho-
gens and the immune mechanisms that are involved in
conferring this protection. However, further studies are
required to identify the factors involved such as the
isotypes of antibody produced, and the role of bacterial
and phage proteins in providing an adjuvant effect.
MATERIALS AND METHODS
Phage clones
Phage clones were isolated from a phage peptide
display library, based on the filamentous phage fd, con-
sisting of ;108 different phage clones, each displaying a
5 amino acid peptide as part of their major coat protein
Grabowska et al., 1999). In addition to a wild-type gene
III encoding the major coat protein pVIII, the phage in
his library were engineered to express a recombinant
orm of gene VIII containing a degenerate DNA insert
ncoding random peptides and are, therefore, Type 88
ectors (Smith, 1993). The recombinant gene VIII is under
he control of a tac promoter; the ratio of the peptide-
isplaying to wild-type pVIII can, therefore, be altered by
arying the concentration of iso-propyl-thio-galactose
IPTG) added to the host bacterial culture.
Eleven phage clones recognised by 4 mAbs (Liljeqvist
t al., 1998) were used: 2.10, 2.11, and 3.19 recognised by
Ab H5; 7.17 and 7.25, mAb H7; 8.13, 8.22, and 9.4, mAb
11; and 12.4, 12.18, and 12.28, mAb E5. Identification and
haracterisation of these clones is described in detail in
rabowska et al. (1999). The sequences of the peptides
s
jisplayed by these phage clones are given in Table 1. In
ddition, the wild-type phage, f88-4 from which the li-
rary was derived, was used.
reparation of PEG-precipitated phage for use as
mmunogens
Phage clones were prepared from a 500-ml overnight
ulture of infected bacteria grown in Terrific Broth with
etracycline (20 mg/ml) to select for phage expression
and IPTG (1 mM) to maximise expression of the recom-
binant gene VIII carrying the peptide insert. f88-4 was
grown in the absence of IPTG as no peptide is displayed
by the recombinant gene VIII.
Bacteria were removed by centrifugation at 10,000 g
maximum in a Sorvall GSA rotor at 4°C. Phage were
precipitated from the supernatant by addition of PEG
8000 and NaCl to final concentrations of 4% and 3%,
respectively, followed by a 45-min incubation at room
temperature with stirring. The phage were pelleted by
centrifugation at 10,000 g at 4°C. The supernatant was
discarded, and the phage pellet was resuspended in
TBS. Insoluble material was removed by a further cen-
trifugation at 10,000 g. The PEG precipitation was then
repeated.
Phage concentration was assessed using the Sigma
BCA assay, using ovalbumen as a standard, according to
the manufacturer’s instructions.
Polymixin B absorption of PEG precipitated phage
For some phage preparations, LPS was absorbed out
of the PEG precipitated phage preparations by passing
them through polymixin B columns (Pierce).
Immunisation
BALB/c mice were obtained from a randomly bred,
closed colony at the Sheffield University animal facility.
Immunisations were administered subcutaneously at
2-week intervals. The dose given is the quantity of phage
used per mouse per immunisation in a 200 ml volume of
TBS. Prebleeds were obtained from a random selection
of the mice prior to immunisation, and further bleeds
were taken from all mice 2 weeks after each immunisa-
tion. Four weeks after the last immunisation, mice were
challenged with 5–6 mouse lethal doses of HSV-2 (strain
333). Survival of the mice was monitored daily.
Analysis of immune response to gG2 by ELISA
Wells were coated with Helix pomatia lectin purified
G2 (gift from Dr. S. Jeansson, Oslo, Norway) at a dilution
f 1:500 in carbonate-bicarbonate buffer, pH 9.6, blocked
ith 30% normal goat serum (NGS) in phosphate-buff-
red saline (PBS), then incubated in turn with mouse
era at a 1:100 dilution and horseradish peroxidase con-
ugated rabbit anti-mouse Ig at 1:1000 in PBS-10% NGS.
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53INDUCTION OF PARTIAL PROTECTIVE IMMUNITY TO HSV-2 BY PHAGE-DISPLAYED PEPTIDESAfter each step, wells were washed with PBS containing
0.05% Tween 20. Fast OPD tablets (Sigma) were used as
a substrate for the peroxidase and the O.D. of each well
was read at 490 nm after stopping the reaction with 2 M
H2SO4.
For each experiment, a random selection of sera from
groups of mice immunised with phage-displayed pep-
tides were analysed for their immune response to gG2,
by titration of the sera. Based on the result of this initial
analysis a single serum dilution was chosen to allow a
comparative analysis of all the sera obtained from that
experiment. Each serum was tested in duplicate; the
results shown in the figures are the average of the two
results.
Tris–tricine polyacrylamide gel electrophoresis (PAGE)
PEG-precipitated phage samples were mixed with an
equal volume of 4% SDS, 20% glycerol, 100 mM Tris–HCl,
pH 8.3, 0.1% bromphenol blue and heated to 100°C for 2
min. The samples were subjected to electrophoresis on
a 15% PAGE gel with a 5% stacking gel, using a 100 mM
Tricine, 100 mM Tris, 0.1% SDS buffer, according to the
method described by Willis et al. (1993). Bands were
visualised using the Sigma Silver staining kit.
Analysis of the antigenicity of phage clones by ELISA
Phage were analysed for their reactivity with the rele-
vant mAbs as described previously (Grabowska et al.,
1999). Briefly, PEG precipitated phage were captured in
ELISA wells using a rabbit anti-fd polyclonal antibody
(Sigma), then incubated in turn with the relevant mAb and
a horseradish peroxidase anti-mouse conjugate. The
signal was developed as described above.
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